88 - References

References
92
The Maudsley® Prescribing Guidelines in Psychiatry
CHAPTER 1
References
Heres S, et al. Pharmacokinetics of olanzapine long-­acting injection: the clinical perspective. Int Clin Psychopharmacol 2014; 29:299–312.
Mitchell M, et al. Single-­ and multiple-­dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-­acting injection: an open-­
label, multicenter, nonrandomized study in patients with schizophrenia. Clin Ther 2013; 35:1890–1908.
Lauriello J, et al. An 8-­week, double-­blind, randomized, placebo-­controlled study of olanzapine long-­acting injection in acutely ill patients
with schizophrenia. J Clin Psychiatry 2008; 69:790–799.
Eli Lily and Company Limited. Summary of Product Characteristics. Zypadhera (olanzapine pamoate monohydrate) 210mg powder and
solvent for prolonged release suspension for injection. 2023 (last accessed August 2024); https://www.medicines.org.uk/emc/product/6429/
smpc.
Denee TR, et al. Treatment continuation and treatment characteristics of four long acting antipsychotic medications (paliperidone palmitate,
risperidone microspheres, olanzapine pamoate and haloperidol decanoate) in the Netherlands. Value Health 2015; 18:A407.
Taipale H, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-­a nationwide study with 20-­year
follow-­up. Schizophr Bull 2017; 44:1381–1387.
O’Neill JR, et al. Implementing gradual, hyperbolic tapering of long-­acting injectable antipsychotics by prolonging the inter-­dose interval: an
in silico modelling study. Ther Adv Psychopharmacol 2023; 13:20451253231198463.
Citrome L. Long-­acting injectable antipsychotics: what, when, and how. CNS Spectr 2021; 26:118–129.
Kochen SA, et al. Olanzapine postinjection delirium/sedation syndrome after long-­acting olanzapine depot injection presenting to the emergency department: practical guidelines for diagnosis and management. Emerg Med J 2024; 41:759–763.
McDonnell DP, et al. Post-­injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-­acting injection,
II: investigations of mechanism. BMC Psychiatry 2010; 10:45.
Podgorná G, et al. Post-­injection delirium/sedation syndrome: a case report and 2-­year follow-­up. Am J Case Rep 2022; 23:e937579.
Seebaluck J, et al. Case series profile of olanzapine post-­injection delirium/sedation syndrome. Br J Clin Pharmacol 2023; 89:903–907.
Bushes CJ, et al. Olanzapine long-­acting injection: review of first experiences of post-­injection delirium/sedation syndrome in routine clinical
practice. BMC Psychiatry 2015; 15:65.
Meyers KJ, et al. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-­acting injection: results
from a large observational study. BJPsych Open 2017; 3:186–192.
Garg S, et  al. Delayed onset postinjection delirium/sedation syndrome associated with olanzapine pamoate: a case report. J Clin
Psychopharmacol 2019; 39:523–524.
Eli Lilly Australia Pty Ltd. Consumer Medicine Information: ZYPREXA RELPREVV® (olanzapine pamoate monohydrate). 2024 (last
accessed August 2024); https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-­2024-­CMI-­01649-­1&d=
20240807172310101.
Pharmaco (N.Z.) Ltd. Consumer Medicine Information: ZYPREXA RELPREVV® (olanzapine pamoate monohydrate). 2023 (last accessed
August 2024); https://www.medsafe.govt.nz/consumers/cmi/z/zyprexarelprevvinj.pdf.
Siskind D, et al. Monitoring for post-­injection delirium/sedation syndrome with long-­acting olanzapine during the COVID-­19 pandemic. Aust
N Z J Psychiatry 2020; 54:759–761.
Venkatesan V, et al. Postinjection delirium/sedation syndrome after 31st long-­acting olanzapine depot injection. Clin Neuropharmacol 2019;
42:64–65.
Anand E, et al. A 6-­year open-­label study of the efficacy and safety of olanzapine long-­acting injection in patients with schizophrenia: a post
hoc analysis based on the European label recommendation. Neuropsychiatr Dis Treat 2015; 11:1349–1357.
Atkins S, et al. A pooled analysis of injection site-­related adverse events in patients with schizophrenia treated with olanzapine long-­acting
injection. BMC Psychiatry 2014; 14:7.